<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2242">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04273763</url>
  </required_header>
  <id_info>
    <org_study_id>2019NCP1.0</org_study_id>
    <nct_id>NCT04273763</nct_id>
  </id_info>
  <brief_title>Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19)</brief_title>
  <official_title>Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital of Wenzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wanbangde Pharmaceutical Group Co., LTD</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Second Affiliated Hospital of Wenzhou Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Compare the efficacy and safety of Bromhexine Hydrochloride Tablets combined with standard
      treatment/ standard treatment in patients with suspected and mild, or common novel
      coronavirus pneumonia (COVID-19).

      Random, open, group sequential design.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 16, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 10, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to clinical recovery after treatment</measure>
    <time_frame>within 14 days from the start of medication</time_frame>
    <description>Defined as random to fever, respiratory rate return to normal and cough remission over 48 hours.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of aggravation</measure>
    <time_frame>within 14 days from the start of medication</time_frame>
    <description>Aggravation was defined as(one of them): respiratory distress, RR ≥ 30 times / min; SpO2 ≤ 93% in resting state; arterial partial pressure of oxygen (PaO2) /concentration of oxygen (FiO2) ≤ 300mmHg</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical remission rate</measure>
    <time_frame>within 14 days from the start of medication</time_frame>
    <description>Clinical remission was defined as (one of them): sustained (more than 48 hours) alleviation of illness based on symptom (fever, cough, dyspnea, myalgia, diarrhea and so on) all being absent and no evidence for progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dynamic changes of oxygenation index</measure>
    <time_frame>within 14 days from the start of medication</time_frame>
    <description>oxygenation index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to cure</measure>
    <time_frame>within 14 days from the start of medication</time_frame>
    <description>time of Clinical recovery, negative COVID-19 nucleic acid results and CT recovery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate to cure</measure>
    <time_frame>within 14 days from the start of medication</time_frame>
    <description>proportion of Clinical recovery, negative COVID-19 nucleic acid results and CT recovery among infected patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to defervescence</measure>
    <time_frame>within 14 days from the start of medication</time_frame>
    <description>defervescence is defined as below 37 Celcius degrees（ear temperature）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to cough remission</measure>
    <time_frame>within 14 days from the start of medication</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to dyspnea remission</measure>
    <time_frame>within 14 days from the start of medication</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days of supplemental oxygenation</measure>
    <time_frame>within 14 days from the start of medication</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients with requring supplemental oxygen</measure>
    <time_frame>within 14 days from the start of medication</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients with mechanical ventilation</measure>
    <time_frame>within 14 days from the start of medication</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of negative COVID-19 nucleic acid results</measure>
    <time_frame>within 14 days from the start of medication</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of negative COVID-19 nucleic acid results</measure>
    <time_frame>within 14 days from the start of medication</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of ICU admission</measure>
    <time_frame>within 14 days from the start of medication</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>28-day mortality</measure>
    <time_frame>From the first day of screening to the day of follow-up (28 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Novel Coronavirus Pneumonia</condition>
  <condition>2019-nCoV</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bromhexine Hydrochloride Tablets</intervention_name>
    <description>Bromhexine Hydrochloride Tablets</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arbidol Hydrochloride Granules</intervention_name>
    <description>Standard treatment refers to the latest edition of Pneumonia Diagnosis and Treatment Scheme for Novel Coronavirus Infection. Arbidol Hydrochloride Granules is recommended but not enforced to use.</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant Human Interferon α2b Spray</intervention_name>
    <description>Standard treatment refers to the latest edition of Pneumonia Diagnosis and Treatment Scheme for Novel Coronavirus Infection.</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged between 18 and 80 years (Including 18and 80years, male or female).

          -  One of them:

               1. Laboratory (RT-PCR) and clinical symptoms confirmed case of novel coronavirus
                  pneumonia (COVID-19).

               2. Patients diagnosed clinically as suspected cases.

          -  Ability to communicate well with researchers and sign the informed consent Form (ICF)
             voluntarily.

        Exclusion Criteria:

          -  ALT≥5 times of ULN, level of total bilirubin≥3 times of ULN, or Cr≥1.5 times of ULN.

          -  Patients with serious severe liver disease.

          -  Excluded who diagnosed as pneumonia patients with novel coronavirus infection of
             severe type and critical type. 【Diagnostic criteria reference the official guideline
             &quot;Pneumonia Diagnosis and Treatment Scheme for Novel Coronavirus Infection (Trial
             Version 5) &quot;】.

          -  Patients with previous history of severe gastrointestinal diseases such as gastric
             ulcers and bleeding.

          -  Patients with lactose intolerance.

          -  Patients who are allergic to the components of this medicine (Major components:
             Bromhexine Hydrochloride; excipient: starch, lactose, magnesium stearate).

          -  Positive serum pregnancy test result for women with childbearing potential at
             screening or lactating women.

          -  Other circumstances that the researcher considers inappropriate to participate in this
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>XIAN SHEN, phd</last_name>
    <role>Study Chair</role>
    <affiliation>The 2nd Affiliated Hospital of Wenzhou Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Second AffIliated Hospital of Wenzhou Medical University</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <zip>325000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>February 14, 2020</study_first_submitted>
  <study_first_submitted_qc>February 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2020</study_first_posted>
  <last_update_submitted>April 29, 2020</last_update_submitted>
  <last_update_submitted_qc>April 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Bromhexine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

